Figure 3.

DC – TMB – CD4⁺ Naive T-cells Trivariate Model for Predicting Immune-Related Adverse Events for Anti–PD-1 Therapy Across Cancer Types (A), Combined effect of dendritic cells abundance (DC) – tumor mutational burden (TMB) – CD4⁺ naive T-cells abundance (naiveCD4T) trivariate model. The dashed line depicts the linear fit, with the formula reporting odds ratio (ROR) = 19.03 × DC + 0.82 × log(TMB) + 18.03 × naiveCD4T – 1.85. (B), Estimated ROR to anti-PD-1 therapy in small cell lung cancer based on TMB univariate model, DC – TMB and TMB – CD4⁺ naive T-cells bivariate models, and DC – TMB – CD4⁺ naive T-cells trivariate model. The dotted line represents the ROR in small cell lung cancer, which was obtained using The US Food and Drug Administration’s Adverse Event Reporting System.